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ABSTRACT 
 
Cyclosporine (CsA) is one of the main immune-suppressant agents which has 
been used widely in organ transplantation against graft rejection. However, the low oral 
bioavailability and the associated adverse effects such as nephrotoxicity are the main 
drawbacks of current usage of this drug. Thus, purpose of this research is to formulate 
PLGA nanoparticles of CsA to improve its effectiveness and to reduce the 
nephrotoxicity induced by the plain drug. CsA-loaded PLGA nanoparticles were 
prepared by the nanoprecipitation method. Particle size and zeta potential of the 
formulation was determined and percent drug entrapment were also determined. 
Quantitative estimation was carried out using validated UV spectroscopic method. The 
morphology of the nanoparticles was determined by Transmission Electron 
Microscopy. In vitro drug release profile was carried out utilizing dialysis method. In 
vitro cytotoxicity using MTT assay and in vivo toxicity studies are in progress and will 
be shared in the next presentations. The developed CsA loaded PLGA were developed 
and optimized having size around 80 nm with less than 0.2 PDI that shows narrow size 
distribution. The result from TEM studies also was in similar with DLS results. Zeta 
potential was found to be -29.32±2.7 mV, describing the stability of formulation. The 
optimized formulation could entrap 47.4±3.2 % of Cy-A in PLGA NPs. In vitro 
cytotoxicity using MTT assay shows fewer toxic effects in HEK-293 cells. CsA loaded 
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PLGA nanoparticles were successfully developed and characterized. The size of the 
particles was in the nanometer range with narrow size distribution. This 
nanoformulations may serve as an alternative formulation for CsA for effective drug 
delivery and to reduce the side effects.
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CHAPTER ONE:  
INTRODUCTION 
 Cyclosporine A (CsA) is one of the main immunosuppressants, that is widely 
used for organ transplantation against graft rejection (Fig. 1). Also, it is widely used for 
the treatment of autoimmune disease more than 30 years (Tedesco & Haragsim, 2012). 
The reason CsA has immunosuppressive activity is attributed to restraining the 
compound calcineurin phosphatase and according to this inhibits the outflow of 
cytokines, for example, IL2 and IFN ϒ and therefore T cell proliferation (Fig. 2) 
(Pradhan, Mohanty, & Sahoo, 2018). However, the low and variable oral bioavailability 
makes CsA toxic for kidneys (Tedesco & Haragsim, 2012). Nephrotoxicity is not the 
only side effects of CsA. There have also been reports of hypertension, anemia, 
paresthesia, hyperesthesia, hirsutism and gingival hyperplasia, altered coagulability, 
hepatotoxicity, neurotoxicity, lymphoproliferative neoplasms, and osteoporosis 
(Pradhan et al., 2018). In this work, nephrotoxicity resulting from CsA will be the 
primary focus. 
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Figure 1. Chemical structure of CsA. 
 
Figure 2. Immunosuppressive action mechanism of CsA. Adapted from Nabel (1999) (E. 
Mervaala et al., 1999) 
The effects of Cyclosporine for transplant medicine were discovered in the lab of 
Sandoz in Switzerland in 1972, and its benefits were revolutionary for transplant 
medicine (Tedesco & Haragsim, 2012). The main reason of discovering CsA depends on 
the inhibition of both in vitro, cell-mediated lysis and lymphocyte sensitization using T 
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cells (Tedesco & Haragsim, 2012). Firstly when cyclosporine was used in clinical trials, it 
showed 94% survival rate, but after continuously using cyclosporine the nephrotoxic 
effects were discovered (Tedesco & Haragsim, 2012). The pathophysiology of the 
nephrotoxicity involves reducing renal blood flow and increasing renal vascular 
resistance (Tedesco & Haragsim, 2012). One of the reasons of this action depends to the 
renal sympathetic nervous system (Tedesco & Haragsim, 2012). Also, cyclosporine 
increases endothelin and thromboxane using renin-angiotensin system (RAS)(Tedesco 
& Haragsim, 2012). There are two key mediators as a macrophages and neutrophils for 
an anti-microbial immunity which their works are reducing depending to the CsA 
(Liddicoat et al 2019). CsA is an endecapeptide, it is extracted from Tolypocladium 
inflatium Gams (E. M. Mervaala et al., 1997). There is an increased risk of chronic 
kidney disease (CKD) associated with CsA (Chiu et al., 2015). According to the clinical 
trial provided by Chiu et al (2015), patients with rheumatoid arthritis (RA) have a  98% 
chance to experience CKD associated with nephrotoxicity (Chiu et al., 2015). That is 
why it is not advised to prescribe CsA by physicians for the elderly patients with 
diagnosed RA (Chiu et al., 2015).  
As mentioned before Cyclosporine is widely used in organ transplantation. This 
includes kidney, liver, heart, lung and pancreases transplantation (Italia, Bhatt, 
Bhardwaj, Tikoo, & Kumar, 2007). It was described that cyclosporine has a low oral 
bioavailability, because of the cyclic structure and high molecular weight. Poor aqueous 
solubility is also one of the challenges of cyclosporine (Italia et al., 2007). Additionally, 
P-glycoprotein, pre-systemic metabolisms and liver reduces oral bioavailability of the 
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cyclosporine. That is not an all-inclusive list of the challenging factors regarding 
cyclosporine. Other than the low and variable oral bioavailability, cyclosporine has a 
critical dose in a narrow therapeutic window, and because of this commercial 
formulation of cyclosporine requires careful dosing protocol to prevent its 
nephrotoxicit. As mentioned before, cyclosporine can cause different forms of kidney 
dysfunction, which is why it is necessary to develop less toxic cyclosporine 
formulations. The main reason of this situation related to the narrow therapeutic 
window of CsA that is why the amount of CsA should be controlled by these 
formulations in the blood vesels (Italia et al., 2007).  
From above, there is low oral bioavailability of cyclosporine and that is not the 
only issues which were investigated for CsA. Use of CsA in the ophthalmology field 
were investigated in 1981, and it was discovered that CsA has an application for corneal 
graft transplantation, in uveitis, corneal healing, vernal keratoconjunctivitis (Lallemand 
et al., 2017). CsA is able to reach different ocular tissues without showing sharp side 
effects as opposed to non-ocular administration (Lallemand et al., 2017). Due to these 
findings some CsA-loaded products have successfully reached to the pharmaceutical 
market place for the treatment of dry eye disease (DED) and other ocular diseases 
keratoconjunctivitis sicca (KCS) (Lallemand et al., 2017). Some of the CsA products are 
shown in the Table 1 according to the article written by Lallemand (2017) (Lallemand et 
al., 2017) 
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Table 1. CsA marketed ocular formulations in different years. Retrieved from 
(Lallemand et al., 2017).  
Product name Company Dosage form Indication Marketed 
since 
Restasis® (0.5 
mg/mL) 
Allergan Anionic 
emulsion (UD) 
DED 2003 
 
Ikervis® (1.0 
mg/mL) 
Santen Pharmaceutical 
Co. Ltd. 
Cationic 
emulsion (UD) 
DED 2015 
Papilock 
mini® 
Santen Pharmaceutical 
Co. Ltd. 
 
Solution (UD) 
 
VKC - vernal 
keratoconjunctivitis 
2005 
Modusik-A 
Ofteno® 
Laboratorios Sophia 
 
Solution (MD) KCS 2003 
Lacrinmune® Bausch & Lomb, Inc. Emulsion (MD) KCS NA 
 
As we can see from Table 1 Restasis® and Ikervis® actually effective for dry eye 
syndrome (DES) and Restasis® has an approval from US Food and Drug 
Administration (FDA), while Ikervis® is already used in European countries (Agarwal 
& Rupenthal, 2016) (Lallemand et al., 2017). However, these products are associated 
with ocular discomfort. In the article named “Modern approaches to the ocular delivery 
of cyclosporine A” written by Agarwal et al (2016) we learn information about different 
CsA Nanoformulations (Agarwal & Rupenthal, 2016). They collect information from 
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different references and describe advantages and limitations of ophthalmic dosage 
forms for CsA to treatment ocular diseases. These drug delivery systems include 
micelles, liposomes, proliposomes, nanospheres – nanocapsules, nanoemulsions, solid 
lipid nanoparticles, in situ gelling systems and hydrogels. Based on that report it is 
possible to develop CsA Nanoformulations for effectively decreasing nephrotoxicity. 
These CsA formulations improve bioavailability and they have target specific ocular 
tissues which increases side effects of cyclosporine (Agarwal & Rupenthal, 2016). CsA 
PLGA nanoparticles did not cause toxicities within dose range (Venkatpurwar et al 
2015). 
Objective 
In this thesis, nanoformulations are used to decrease CsA nephrotoxicity. The 
focus is on comparing three Cyclosporine A nanoformulations. These nanoformulations 
include CsA PLGA nanoformulations with different concentration and weight ratio. 
Also, there are research articles demonstrating how antioxidants are helpful to decrease 
CsA nephrotoxicity (Sonaje et al., 2007). According to Sonaje et al (2007) ellagic acid 
(EA) improves oral bioavailability of CsA if it encapsulates the poly (lactide-co-
glycolide) (PLGA) and polycaprolactone (PCL) nanoparticles and in this case the 
suggesting dose decreases for three times (Sonaje et al., 2007).  
Also, it is known that PLGA nanoparticles increases bioavailability of the drug 
comparing to their free form (Simon et al 2016). According to the Zhang et al (2015) CsA 
nanomicelle eye drops (CNED) shows better effects compared to the conventional CsA 
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eye drop (CCED) (Zhang, Wang, & Zhang, 2015). It was reported that CNED has better 
response by corneal transplantation (Zhang et al., 2015).  
CsA oil-in-water nanoemulsion formulations also, can be effective in the brain 
for intranasal or intravenous administration, because it efficiently transports into the 
brain through the blood-brain barrier (Yadav, Gattacceca, Panicucci, & Amiji, 2015). The 
brain is not the only organ who showed effective response by CsA Nanoformulations 
on the animal studies. According to the Behr et al (2009) liposomal CsA PARI 
formulation shows increasing survival chances and there are no side effects related to 
the drug. (Behr et al., 2009). CsA loaded PLGA/polymeric liposomes also could be 
effective against spinal cord injury (SCI) (Gao et al 2017). 
Nanotechnology increased the area of drug delivery field research, and different 
nano carrier increases poor oral bioavailability. There are few products on the market 
and clinical trials which uses nanotechnology-based oral formulations. Of course, there 
are two product of cyclosporine which uses nanotechnology: Sandummine Neoral ® 
and Gengraf ® (Desai et al 2012). Both these products use a system for spontaneously 
emulsifying and the dosage form of first of them is soft gelatin capsule, for the second 
one it is hard gelatin capsule. Sandummine Neoral ® is a product of Novartis Company 
and Gengraf ® is a product of Abbott Laboratories (Desai et al 2012).  
Both these products have an immunosuppressant activity, increased 
bioavailability compared to cyclosporine and oily formulation of the previous product 
(Desai et al 2012). However, these formulations may increase the oral bioavailability, 
but they failed to decrease nephrotoxicity of CsA compared to cyclosporine loaded 
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PLGA nanoparticle (Italia et al., 2007). That is why in this research searching the 
appropriate cyclosporine loaded PLGA nanoparticle formulations is one of the goals for 
CsA. 
Nanoemulsion formulations of CsA are also effective for reducing nephrotoxic 
side effects (Ganta et al 2014). According to the Ganta et al (2014), CsA nanoemulsion 
formulation using oil such as soybean oil and egg lecithin composition showed 
reducing nephrotoxic side effects which happened because of CsA drug compare to 
other nanoformulation - a Cremophor®EL/ethanol-based CsA(Sandimmune® 
Injection) (Ganta et al 2014). This example shows that even nanotechnology decreases 
the nephrotoxic side effects, but different nanoformulations reduces differently. In this 
research nanoformulations will be prepared using different research materials which 
were effective for decreasing nephrotoxicity according to the reviewed articles. 
Nanoformulations will be characterize using particle size and zeta potential methods 
and toxicity will be checked by cell line studies. In the end, it will be obvious which 
PLGA nano formulation is more effective for decreasing CsA nephrotoxicity. 
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CHAPTER TWO: 
MATERIALS AND METHODS 
Materials 
CsA and PLGA, lactide/glycolide ratio of 50:50 was purchased from the Acros 
Organics (NJ, USA). Polyvinyl alcohol, Fetal Bovine Serum, penicillin-streptomycin and 
Trypsin (0.05%) were obtained from  Fisher Scientific (USA). Dialysis membrane, MW 
cutoff 10000 was purchased from Sigma Aldrich (St. Louis, MO)., USA. MTT reagent [3-
(4,5-dimethylthiazol-2-yr)-2,5-diphenyltetrazolium bromide salt] was outsourced from  
Tocris Bioscience (MN, USA). 293 [HEK-293], a human embryonic kidney cell line 
(ATCC® CRL1573™) and Eagle’s minimum essential Medium (EMEM) was purchased 
from American Type Culture Collection (ATCC) (VA, USA). Phosphate Buffer Saline 
(1X) (PBS) was obtained from Corning Cellgro (Manassas, VA). All the analytical 
reagents were of analytical grade quality. 
Preparation of CsA loaded PLGA NPs 
CsA-NPs were prepared via the oil in water emulsion solvent evaporation 
method (Naeem et al 2018). The CsA drug and the PLGA were dissolved in a 1 mL of 
acetone as organic phase at a weight ratio of 1:7. The organic solution was slowly added 
into pH 9 deionized water with 23-gauge syringe while constantly stirring at 700 rpm at 
room temperature overnight for evaporation of solvent. The nanoparticulate suspension 
obtained was centrifuged at 5000 rpm during 5 mins then centrifuged at 18000 rpm at 4 
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ºC 15 mins. After centrifugation, pelleted nanoparticles were collected washed thrice 
with distillated water. Blank nanoparticles were prepared in the same manner. 
Particle Size and Zeta Potential 
Particle size and polydispersity index (PDI) of CsA-NPs were measured by 
dynamic light scattering (DLS). Measurement of Size, PDI and Zeta Potential was 
performed triplicate at 25 °C temperature after proper dilution of prepared CsA-NPs 
formulation by using Zeta sizer (Nano ZS90, Malvern Instruments Ltd., UK, Zeta Sizer 
Software Ver. 7.10). The results were shown as Z-average and polydispersity index 
(PDI). This analysis was carried out using a detection angle of 90 º at a temperature of 
approximately 25 ºC for each sample, adequately diluted with filtered distilled water. 
Transmission Electron Microscopy 
Morphology and shape of CsA-NPs was obtained by transmission electrode 
microscope (TEM) (JEOL JEM 1400 electron microscope with Gaton camera, Peabody, 
MA, USA). Sample preparation included drop casting onto a formvar coated copper 
support film square grid having 200 mesh. Then it was allowed to air dry 5 to 10 
minutes followed by treatment with 2% w/v phosphotungstic acid for negative 
staining. Voltage of about 120 kV with 40,000 magnification was used to conduct the 
imaging. 
Calibration curve UV Method 
2 mg of CsA was dissolved in 2 mL of methanol then diluted as appropriate for 
six different concentrations: 5 µg/mL, 20 µg/mL, 40 µg/mL, 50 µg/mL, 60 µg/mL and 
80 µg/mL.  
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Then absorbance was determined using UV spectroscopy at 210 nm (λmax) 
wavelength. All concentrations were repeated three times for averaging in order to 
obtain the calibration curve.  
Entrapment Efficiency 
CsA-NPs was centrifuged after synthesis as mentioned in the preparation of 
formulation section, then 100 µl of product was taken and added into 2900 µl methanol. 
After sonication, absorbance of the formulation was analyzed by using UV 
spectrophotometer at a wavelength of 210 nm (λmax). The entrapment efficiency was 
calculated using the equation below.  
% Entrapment efficiency =
Actual amount of drug loaded in nanoparticles
Actual amount of drug used for preparation
 𝑋 100 
Differential Scanning Calorimetry (DSC) 
Differential scanning calorimetry (DSC) was used to determine the thermal 
behavior of the CsA drug, PLGA, physical mixture of the CsAnd PLGA and CsA- NPs 
formulation respectively. This study conducted by using the DSC- Q 20 (TA 
Instruments, New Castle, DE USA, Q series Q20-2288-DSC software). Briefly, 5 mg of 
the sample was used while taking a blank aluminum pan as reference. Then altogether 
heated from 30 ºC to 300 ºC at a rate of 10°C/ min under the nitrogen purge (15). 
Cytotoxicity Analysis 
The MTT assay was performed to determine the level of cytotoxicity associated 
with the CsA-NPs comparing it with the CsAdrug solution, in 293 [HEK-293], a human 
embryonic kidney cell line (ATCC® CRL1573™). The cells were seeded at a suitable 
density of 5000 cells/well in a 96 well plate in 200 μl of EMEM supplemented with 10% 
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FBS. After 24 hours of incubation at 37 °C, 5% CO2 for 24 h till reaches cell confluency. 
After 24 hr incubation, the cells were treated with prepared EMEM and washed with 
sterile PBS then treated with both formulations and drug solutions in different 
concentrations. The treatment was kept for 4 hours then cells were washed once with 
sterile 1X PBS and added fresh complete EMEM medium containing 10% FBS for period 
of 24 to 48 h. After 24 hours, 100 µl of MTT reagent (1 mg/mL) solution replaced 
complete media followed by next 4 hours incubation. Then added 100 µl of dimethyl-
sulfoxide. The intensity of the color of the formazan crystals was measured via 
microtiter plate reader at wavelength 595 nm. Cells treated with EMEM acted as the 
negative control while the cells were treated with Triton X were the positive control.   
Statistical Analysis 
All analyses were tested in triplicate. Data are represented as mean ± standard 
Deviation. NOVA, Student’s t-test and GraphPad Prism (version 6, USA) was used for 
all analyses.  
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CHAPTER THREE: 
RESULTS 
Particle Size and Zeta Potential 
The size of CsA-NPs was determined by using DLS technique and was found to 
be 79.64 ±1 nm with PDI of 0.09 ± 0.01. The mean zeta potential of CsA-NPs was found 
around -40.01±0.5 mV measured by Malvern zeta sizer Nano ZS90.  Figure 3(A) shows 
Z-average for the particle size for CsA-NPs, (B) is the Zeta Potential for the formulation. 
 
Figure 3: Average size of CsA-NPs 
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Figure 4: Zeta potential image of CsA-NPs  
Transmission Electron Microscopy  
The particle size of the CsA-NPs was found around 200 nm via TEM. Even 
though this particle size here is different from the size obtained from the DLS 80 nm, 
this difference can be explained by the different working property of the two studies. 
DLS gives the hydrodynamic diameter of the formulation while the TEM exhibits the 
size of the formulation fixed in grid. Figure 4 shows the uniform size and spherical 
surface.  
15 
 
 
Figure 5: TEM image of CsA-NPs with 40,000X magnification ataccelerating voltage of 
120 kV (scale bar 0.5 μM). 
 
Entrapment Efficiency 
Entrapment efficiency, was found 68% ± 3.5% by the equation given above, 
adding the CsA-NPs formulation into Methanol. Encapsulation efficiency was 
determined by using UV spectroscopy in methanol at 210 nm (λ max). 
Calibration Curve UV Method 
UV calibration curve of CsA was performed to help to calculate entrapment 
efficiency. Five different concentrations were checked by using UV spectroscopy at 210 
nm triplicate. As figure 5 shown below R2 =0.9995.  
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Figure 6: CsA calibration curve 
Differential Scanning Calorimetry (DSC) 
DSC was performed to help to know the compatibility of the CsAnd PLGA 
nanoparticles. As figure 6 shown below, the characteristic melting point of CsAis 208 
⁰C. And this pick is showing in the physical mixture of CsAnd PLGA while not 
showing in the picture CsA-NPs formulation, indicating that the CsAis loaded in PLGA 
Nanoparticles.  
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Figure 7: DSC spectra of CsA pure drug, PLGA, CsA and PLGA physical mixture and 
CsA-NPs formulation. 
 
Cytotoxicity Study 
The cytotoxicity of the CsA drug solution and CsA-NPs was studied by using the 
MTT assay in human kidney cells (HEK-293). Cells were treated with different 
concentrations (0, 0.001, 0.01, 0.1, 1, 10 and 20 μM) of CsA drug solution and CsA-NPs 
in triplicates for 24 and 48 h. As figure 7 shown below, results demonstrated the cell 
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viability for CsA-NPs formulation is higher than at almost all concentrations, while the 
cell viability for the drug solution was found 81% and 76% respectively at 10 µM and 20 
µM concentrations. Therefore, showing the cell compatibility of the CsA-NPs 
formulation.  
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Figure 8: % cell viability at different concentrations of CsA drug solution and CsA-NPs 
at (A) 24 h and (B) 48 h in HEK-293 cell line, (mean ± SD, n =3). 
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CHAPTER FOUR: 
CONCLUSIONS AND FUTURE PROSPECTS 
CsA loaded PLGA nanoparticles were successfully developed and characterized. 
The size of the particles was in the nanometer range with narrow size distribution.  
CsA-NPs formulation is able to achieve sustained drug delivery from the drug release 
study. It is determined from the cytotoxicity study that the CsA-NPs is less toxic to the 
HEK- 293 cells. Thus, this nanoformulations may serve as an alternative formulation for 
CsA for effective drug delivery and to reduce the side effects. For future studies this 
CsA PLGA nanoformulation could be compared using MTT assay with other CsA 
nanoemulsion and liposomes. 
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